In terms of CAR-T therapy, by constructing recombinant tumor targeted adenovirus expressing CD19 tags, tumors with different antigens can be labeled as a single anti-CD19 CAR-T recognition target, which can become a powerful supplement to anti antigen mismatched solid tumor immunotherapy [263]. This evidence concerns the gene CD19 and neoplasm.